On the occasion of the anniversary of Nikolay P. Goncharov

In January 2020, the famous scientist biochemist-endocrinologist, MD, professor Nikolay P. Goncharov turned 85 years old. Nikolay P. Goncharov one of the leading experts in the field of biochemical endocrinology and hormonal analysis; he developed and introduced in the framework of the Human Reproduction program an experimental model for evaluating the pharmacokinetics, mechanism of action, efficacy and safety of new steroid drugs and regulators of endocrine secretion of steroid hormones. The editorial board of the journal Problems of Endocrinology congratulates NP Goncharov on his anniversary, wishes him good health, success, prosperity, vitality, fortitude and many more years of fruitful activity.

Download Full-text

Nikolai Petrovich Goncharov (To his 60th birthday)

Problems of Endocrinology ◽

10.14341/probl11379 ◽

1995 ◽

Vol 41 (2) ◽

pp. 47-47

Author(s):

Editorial team of Problems of endocrinology

Keyword(s):

Steroid Hormones ◽

Endocrine System ◽

Human Reproduction ◽

Human Leukemia ◽

Endocrine Glands ◽

Medical Sciences ◽

Scientific Papers ◽

Endocrine Secretion ◽

Hormonal Analysis

60 years have passed since the birth of the famous scientist biochemist-endocrinologist, head of the laboratory of biochemical endocrinology and hormonal analysis of the Endocrinology Research Center of the Russian Academy of Medical Sciences, doctor of medical sciences, professor Nikolai Petrovich Goncharov. He is a pioneer in the study of the synthesis and metabolism of steroid hormones in primates; he developed and implemented an adequate experimental model within the framework of the WHO Human Reproduction program to evaluate the pharmacokinetics, mechanism of action, efficacy and safety of both new steroid preparations and regulators of endocrine secretion of steroid hormones. A significant section of the research of N.P. Goncharov is devoted to a comparative study of the endocrine system of primates, the endocrine support of the stress response, the formation of the function of the endocrine glands in various periods of postnatal ontogenesis, and the role of steroid hormones in the pathogenesis of human leukemia. He is an author of about 200 scientific papers on various problems of hormone biochemistry and endocrinology.

Download Full-text

Urinary bisphenol A in women with polycystic ovary syndrome – a possible suppressive effect on steroidogenesis?

Hormone Molecular Biology and Clinical Investigation ◽

10.1515/hmbci-2020-0032 ◽

2021 ◽

Vol 0 (0) ◽

Author(s):

Zora Lazúrová ◽

Jana Figurová ◽

Beáta Hubková ◽

Jana Mašlanková ◽

Ivica Lazúrová

Keyword(s):

Polycystic Ovary Syndrome ◽

Bisphenol A ◽

Steroid Hormones ◽

Polycystic Ovary ◽

Suppressive Effect ◽

Human Reproduction ◽

Control Group ◽

Ovary Syndrome ◽

Ovarian Steroidogenesis ◽

The Relationship

Abstract Objectives There is a growing evidence indicating an impact of endocrine distrupting chemicals such as bisphenol A (BPA) on human reproduction. Its higher levels in serum or urine have been documented in women with polycystic ovary syndrome (PCOS), however the relationship to ovarian steroidogenesis remains unclear. Aim of the study was to compare urinary BPA (U-BPA) concentrations among PCOS women and control group. Second aim was to assess the relationship of U-BPA to ovarian steroidogenesis in the group with PCOS. Methods Eighty six Caucasian women (age 28.5 ± 5.1 years) diagnosed with PCOS and 32 controls of age 24.9 ± 4.4 years were included in the study. Fasting blood samples were analyzed for biochemical parameters and steroid hormones. U-BPA was measured in the morning urine sample using high pressure liquid chromatography. Results PCOS women had significantly higher U-BPA as compared with control group (p=0.0001). Those with high levels of U-BPA (U-BPA ≥2.14 ug/g creatinine) demonstrated higher serum insulin (p=0.029) and HOMA IR (p=0.037), lower serum estrone (p=0.05), estradiol (p=0.0126), FSH (p=0.0056), and FAI (p=0.0088), as compared with low-BPA group (U- BPA <2.14 ug/g creatinine). In PCOS women, U-BPA positively correlated with age (p=0.0026; R2=0.17), negatively with estradiol (p=0.0001, R2=0.5), testosterone (p=0.0078, R2=0.15), free-testosterone (p=0.0094, R2=0.12) and FAI (p=0.0003, R2=0.32), respectively. Conclusions PCOS women have significantly higher U-BPA concentrations than healthy controls. U-BPA positively correlates with age and negatively with ovarian steroid hormones suggesting a possible suppressive effect of bisphenol A on ovarian steroidogenesis.

Download Full-text

Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability

Depression Research and Treatment ◽

10.1155/2011/680194 ◽

2011 ◽

Vol 2011 ◽

pp. 1-7 ◽

Cited By ~ 3

Author(s):

Silvio Bellino ◽

Paola Bozzatello ◽

Camilla Rinaldi ◽

Filippo Bogetto

Keyword(s):

Borderline Personality Disorder ◽

Pilot Study ◽

Personality Disorder ◽

Adverse Events ◽

Mechanism Of Action ◽

Severity Index ◽

Borderline Personality ◽

Controlled Trials ◽

Efficacy And Safety ◽

Dsm Iv

Antipsychotics are recommended for the treatment of impulsive dyscontrol and cognitive perceptual symptoms of borderline personality disorder (BPD). Three reports supported the efficacy of oral risperidone on BPD psychopathology. Paliperidone ER is the metabolite of risperidone with a similar mechanism of action, and its osmotic release reduces plasmatic fluctuations and antidopaminergic effects. The aim of this study is to evaluate efficacy and safety of paliperidone ER in BPD patients. 18 outpatients with a DSM-IV-TR diagnosis of BPD were treated for 12 weeks with paliperidone ER (3–6 mg/day). They were assessed at baseline, week 4, and week 12, using the CGI-Severity item, the BPRS, the HDRS, the HARS, the SOFAS, the BPD Severity Index (BPDSI), and the Barratt Impulsiveness Scale (BIS-11). Adverse events were evaluated with the DOTES. Paliperidone ER was shown to be effective and well tolerated in reducing severity of global symptomatology and specific BPD symptoms, such as impulsive dyscontrol, anger, and cognitive-perceptual disturbances. Results need to be replicated in controlled trials.

Download Full-text

Scientific School of Professor Sergey Vasilievich Dyakov: in Memory of the Teacher

Narkokontrol ◽

10.18572/2072-4160-2016-3-45-48 ◽

2016 ◽

Vol 3 ◽

pp. 45-48

Author(s):

Aleksandr V. Fedorov ◽

Keyword(s):

Criminal Law ◽

The State ◽

Scientific School ◽

Internal Security ◽

Famous Scientist ◽

Constitutional Order ◽

Integrated Study

The article is dedicated to the memory of the famous scientist, Professor Sergey Vasilyevich Dyakov, who was for many years the member of the Editorial Board of the magazine «Narkokontrol». It reports on the Scientific School of S.V. Dyakov, based on an integrated study of the criminal-legal and criminological positions of crimes against constitutional order and internal security of the State; on Sergey Vasilyevich and his life’s journey, and contains the information about his primary publications concerning criminal law and criminology.

Download Full-text

Again about carbonic anhydrase inhibitors: modern aspects of the use of ICA in ophthalmology

Archive of Ukrainian Ophthalmology ◽

10.22141/2309-8147.9.2.2021.241511 ◽

2021 ◽

Vol 9 (2) ◽

pp. 64-71

Author(s):

P.A. Bezdetko

Keyword(s):

Antioxidant Activity ◽

Intraocular Pressure ◽

Optic Nerve ◽

Carbonic Anhydrase ◽

Macular Edema ◽

Mechanism Of Action ◽

Corneal Endothelium ◽

Complex Treatment ◽

Efficacy And Safety ◽

Carbonic Anhydrase Inhibitors

For more than 70 years, the inhibitors of carbonic anhydrase (ICA) have been used in the treatment of glaucoma. Since 1995, topical forms of ICA have appeared among antiglaucoma drugs — dorzolamide, and since 1999 — brinzolamide. The hypotensive efficacy and safety of topical ICA gave rise to the widespread use of these drugs in the treatment of various forms of glaucoma. The peculiarities of the mechanism of action made it possible to create on their basis effective fixed combinations, which allow reducing the intraocular pressure by up to 40 % in patients with glaucoma. The attractiveness of the drug has expanded due to the effect of ICA on various tissues of the organ of vision. Thus, ICAs effectively improve the hemodynamics of the eye and optic nerve. The antioxidant activity of the drug makes it possible to expand the indications for its use in patients with vascular patho-logy of the retina and optic nerve. The biomechanical characte-ristics of the drug allowed its effective and safe use in the complex treatment of macular edema of various etiologies. The adjuvant use of topical ICAs expands the possibilities of anti-VEGF therapy in the treatment of macular edema of various etiologies. Features of the action of ICA on the endothelial pump function of the cornea made it possible to formulate the rules for the use of topical ICA in patients with an insufficient function of the corneal endothelium.

Download Full-text